Page last checked
Goal
These four peptides have very different healing evidence. LL-37 has human ulcer studies; BPC-157, TB-500 and KPV do not have comparable controlled injury trials here.
Source: Based on 4 compound guides · checked 2026-09-07
Source: Based on 4 compound guides · checked 2026-09-07
BPC-157 and TB-500 are often discussed together for tendon, ligament and muscle injuries. The records here do not include a completed controlled trial of the pair for those injuries.
Small human reports, animal experiments and ulcer trials answer different questions. Each row explains what was studied and what the result can support.
Compounds covered
4
FDA-approved for this goal
0
Being tested for this goal
0
Reported use only
3
Start with the outcome
Recovery is not one outcome. A torn tendon, an open wound, a bowel waking after surgery and function after a stroke are four different research questions.
No controlled human injury trial
BPC-157 and TB-500 are often discussed for these injuries. Neither record carries a completed controlled trial in a person healing one of these injuries.
Read the two-compound evidence guideA human topical trial exists
LL-37 was tested on venous leg ulcers. Two lower strengths improved healing; the highest did not beat placebo. That is wound evidence, not a tendon result.
Open the LL-37 recordTwo placebo-controlled trials
Ipamorelin was tested after bowel surgery. Both completed phase 2 trials measured return of gut function, and neither beat placebo on its main endpoint.
Read what the ipamorelin trials foundOlder human studies, different route
Semax studies followed people after ischemic stroke and used nasal drops. They do not show an injectable sports-recovery protocol.
Open the Semax evidence guideCheck the condition, species and route in each row. A wound-healing result does not automatically apply to a tendon or muscle injury.
| Compound | What people take it for | What research shows | Evidence |
|---|---|---|---|
| BPC-157 | Taken hoping to heal faster — tendon and ligament injuries, muscle tears, and gut conditions such as inflammatory bowel disease.Reported use only | Nearly all of it comes from rats and mice. Three small reports describe people receiving it, none with a comparison group, covering fewer than 30 subjects between them. None of the three tested a healing injury, and none used an injection under the skin. | no human dose shown to workDose reported in the literature only |
| TB-500 | Sold for tendon, muscle and joint injuries, often alongside BPC-157.Reported use only | The full thymosin beta-4 protein reached clinical studies involving eye, wound and heart conditions. FDA identifies TB-500 as a short fragment and reports that it has not identified human exposure data for that fragment. | indirect evidenceNo human dose published |
| LL-37 | Sought for chronic wounds and infections involving biofilms.Measured in a human study | Human venous-ulcer studies measured healing directly. Two lower strengths improved healing in the cited study, while the highest did not beat placebo. The findings apply to that wound treatment, not to every kind of injury. | limited human dataDose from a human trial · no FDA label |
| KPV | Sought for gut inflammation and inflamed skin.Reported use only | Mouse colitis studies and cell experiments measured changes in inflammatory signals. FDA reports that it has not identified human exposure data for KPV by any route. This does not show a human healing dose. | no human dose shown to workNo human dose published |
LL-37 has been studied on venous leg ulcers. That is direct human wound research, but it does not show that LL-37 repairs a torn tendon.
FDA identifies TB-500 as a seven-amino-acid fragment of thymosin beta-4. Trials of the full 43-amino-acid protein do not show the effects of that fragment. FDA reports that it has not identified human exposure data for the fragment.
BPC-157’s small human reports used different routes and had no comparison group. Reports of pain or symptoms do not show that an injured tissue healed faster.
The records reviewed here do not include a completed controlled trial for a torn tendon, strained muscle or injured joint. That leaves the central sports-recovery question unresolved.
Venous leg ulcers are a different condition from sports injuries. The LL-37 findings should stay attached to the wounds and preparations actually studied.
Every purpose, and what backs each one
The evidence-state map for peptides and cancer
The testosterone table, basis by basis
Where the skin evidence stops
How LL-37 differs from the rest of its class
KPV without an approved label: what exists instead
TB-500 — class, half-life and regulatory standing
Which anxiety and depression claims have a trial